|
|
Myelodysplastic Syndromes
|
|
Myelodysplastic Syndromes
[an error occurred while processing this directive]
Seattle Genetics targets leukemia Nov 18, 2005
The study will target patients with acute myeloid leukemia, a cancer of the blood and bone marrow, and related myelodysplastic syndromes who are not eligible ...
- Everett Navy Base News,
Face of Leukemia 2006 calendar benefits Leukemia Research ... Nov 16, 2005
The LRF has been fighting the battle against leukemia, lymphoma and myelodysplastic syndromes for 60 years by funding research into their causes and cures, and ...
- Rock River Times,
Bytes, November 21 Nov 21, 2005
...of Boulder, an interactive and strategic marketing firm, launched a new Web site for the Aplastic Anemia and Myelodysplastic Syndromes International Foundation ...
- Rocky Mountain News,
REVLIMID(R) Marketing Authorization Application Accepted by EMEA ... Oct 26, 2005
REVLIMID Being Evaluated by the EMEA as Oral Targeted Therapy for Treatment of Patients with Myelodysplastic Syndromes (MDS) with Deletion 5q Chromosomal ...
- PR Newswire (press release),
FDA Approvals: Exjade, Oncaspar, Invanz Nov 17, 2005
...the maintenance or reduction of iron burden in transfused patients with thalassemia, sickle cell disease, and other rare anemias and myelodysplastic syndromes. ...
- Medscape (subscription)
MGI PHARMA and SuperGen Provide Regulatory Status Updates for ... Nov 15, 2005
...confirms that the phase 3 trial of Dacogen injection met its co-primary endpoint of overall response rate (ORR) in patients with myelodysplastic syndromes (MDS ...
- PR Newswire (press release),
Pharmion Confirms Vidaza(R) European Regulatory Status Nov 17, 2005
Pharmion is currently sponsoring a study of 354 high-risk myelodysplastic syndromes (MDS) patients comparing Vidaza to best supportive care (BSC) with or ...
- Biotech Intelligence (press release),
Seattle Genetics Initiates SGN-33 Clinical Trial Nov 17, 2005
...a phase I clinical trial of SGN-33, a humanized anti-CD33 monoclonal antibody, for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS ...
- Business Wire (press release),
Reduced-Intensity Allogeneic Stem Cell Transplants with ... Nov 16, 2005
Patients treated were diagnosed with non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia ...
- Cancer Consultants (press release),
Celgene Corporation Reports Strong Operating, Regulatory and ... Nov 3, 2005
Application (MAA) Accepted by the EMEA to Evaluate REVLIMID as Oral Targeted Therapy for Treatment of Patients with Myelodysplastic Syndromes (MDS) with ...
- PR Newswire (press release),
Exjade(R), a Breakthrough Once-Daily Oral Iron Chelator, Receives ... Nov 2, 2005
Approval makes iron chelation more accessible to patients suffering from diseases such as sickle cell, thalassemia and myelodysplastic syndromes EAST HANOVER ...
- PR Newswire (press release),
Celgene Corporation Reports Strong Operating, Regulatory and ... Nov 3, 2005
...to advance US and European regulatory filings, Celgene increased R&D expenditures in REVLIMID(R) regulatory programs in myelodysplastic syndromes and multiple ...
- PR Newswire (press release),
REVLIMID(R) Marketing Authorization Application Accepted by EMEA ... Oct 27, 2005
...authorization to market REVLIMID as a treatment for transfusion-dependent anemia due to low- or intermediate-1- risk myelodysplastic syndromes (MDS) associated ...
- PR Newswire (press release),
MGI, SuperGen, pull European drug application Nov 15, 2005
...about the injectable drug, Dacogen. The agency is considering whether to approve it to treat myelodysplastic syndromes, or MDS.
- Reuters
UPDATE 2-FDA requests more information on cancer drug Nov 15, 2005
Last month, however, the FDA delayed approving the drug as a treatment for a group of blood disorders called myelodysplastic syndromes, or MDS, and requested ...
- Reuters
Exjade Wins FDA Approval as Oral Iron Chelator Nov 2, 2005
...two and older whose iron overload resulted from frequent blood transfusions for thalassemia and sickle cell disease, rare anemias, and myelodysplastic syndromes ...
- MedPage Today,
FDA Sends Second Approvable Letter For Celgene's Thalomid Nov 15, 2005
The agency's Oncologic Drugs Advisory Committee had voted 10-5 in favor of approving the drug for myelodysplastic syndromes, and Raymond said that drug has the ...
- BioWorld Online (subscription),
Exjade, a Breakthrough Once-Daily Oral Iron Chelator, Receives ... Nov 3, 2005
...treat certain types of rare chronic blood disorders, including thalassemia and sickle cell disease as well as other rare anemias and myelodysplastic syndromes. ...
- DG News
Structure of the Hematological Cancer Market and Its Perspectives Nov 3, 2005
...intracellular pathways--under development at a multitude of small oncology companies for leukemias and myelodysplastic syndromes, lymphomas (Hodgkin's disease ...
- Business Wire (press release),
Senate approves Neilson nomination to federal appeals court Oct 27, 2005
Neilson underwent a bone marrow transplant two years ago for treatment of myelodysplastic syndromes, a group of disorders in which the marrow doesn't produce ...
- Detroit Free Press,
Cholestech 2Q sales and profit jump Oct 26, 2005
The drug, Dacogen, is an injection for myelodysplastic syndromes, a condition in which bone marrow does not produce enough blood cells. ...
- San Jose Mercury News,
Pharmion Reports Third Quarter 2005 EPS of $0.27, Nine Month EPS ... Oct 25, 2005
Regulatory and Development Update Pharmion is currently sponsoring a study of 354 high-risk myelodysplastic syndromes (MDS) patients comparing Vidaza to best ...
- PR Newswire (press release),
MGI PHARMA and SuperGen Provide Regulatory Updates for Dacogen(TM) ... Oct 26, 2005
...(Nasdaq:SUPG) today provided a regulatory updates for Dacogen(TM) (decitabine) injection for the treatment of myelodysplastic syndromes (MDS). ...
- Genetic Engineering News,
Cytokinetics, Incorporated Reports Third Quarter 2005 Financial ... Oct 26, 2005
...standard therapies and the other clinical trial is enrolling patients with acute leukemia, chronic myelogenous leukemia or advanced myelodysplastic syndromes. ...
- Yahoo! News (press release)
Vfendâ„¢ Reduces Infection of Central Nervous System in Cancer ... Oct 26, 2005
...cancers are cancers that originate within blood cells; they include different forms of leukemias, lymphomas, multiple myeloma, or myelodysplastic syndromes. ...
- Cancer Consultants (press release),
MGI Pharma, Supergen fall on Dacogen delay Oct 26, 2005
MGI Pharma and Supergen have been seeking to have an injected form of Dacogen approved in the US and EU to treat myelodysplastic syndromes, a group of diseases ...
- MarketWatch
SuperGen, MGI Pharma say Europe may want more drug data Oct 26, 2005
Dacogen is designed to treat myelodysplastic syndromes, a group of diseases in which bone marrow does not produce enough blood cells.
- East Bay Business Times,
REVLIMID(R) PDUFA Date Extended Three Months By FDA 03 Oct 2005
...lenalidomide), for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated ...
- PR Newswire (press release)
FDA Panel Recommends Approval of Exjade® for once-daily oral ... 03 Oct 2005
...transfusions used to treat certain rare, chronic blood disorders, including thalassemia, sickle cell disease, other rare anemias and myelodysplastic syndromes. ...
- Medical News Today (press release)
US Panel Supports Celgene Drug Revlimid for Myelodysplastic ... Sep 15, 2005
A US advisory panel on Wednesday voted 10-5 to recommend approval of Celgene Corp.'s Revlimid to treat anemia in patients with myelodysplastic syndromes. ...
- Cancerpage.com
UPDATE 2-Celgene expects Revlimid trial to resume quickly Sep 28, 2005
...as Celgene is hoping for US approval next week of Revlimid for treatment of certain patients with a group of blood disorders called myelodysplastic syndromes. ...
- Reuters
Biotech Stocks Drug stocks climb; Incyte tumbles Sep 28, 2005
...of the FDA had recommended earlier this month that the drug be approved for the treatment of certain blood cancers known as myelodysplastic syndromes, or MDS. ...
- MarketWatch
Cytokinetics and GlaxoSmithKline Amend Collaboration Agreement for ... Sep 27, 2005
...standard therapies and the other clinical trial is enrolling patients with acute leukemia, chronic myelogenous leukemia or advanced myelodysplastic syndromes. ...
- PharmaLive.com (press release)
Revlimid Trial Stopped: Report Sep 28, 2005
...advisory committee voted to support the approval of Revlimid for patients with transfusion-dependent anemia stemming from myelodysplastic syndromes, a group of ...
- TheStreet.com
ODAC recommends Revlimid for low to intermediate-1-risk MDS ... Sep 15, 2005
Lenalidomide ) for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes ( MDS ) associated ...
- Xagena.it
US advisers back Celgene blood disorder drug Sep 14, 2005
Corp.'s Revlimid is effective in treating anemia in certain patients with potentially fatal blood disorders known as myelodysplastic syndromes and should be ...
- Reuters.uk
UPDATE 3-US advisers back Celgene blood disorder drug Sep 14, 2005
Research) Revlimid is effective in treating anemia in certain patients with potentially fatal blood disorders known as myelodysplastic syndromes and should be ...
- Reuters
Celgene's Revlimid Phase II Data Sufficient For Full Approval In ... Sep 14, 2005
FDA’s Oncologic Drugs Advisory Committee recommended full approval of Celgene’s Revlimid for myelodysplastic syndromes based on Phase II data. ...
- FDA Advisory Committee
FDA Advisory Panel Backs an Anemia Drug Sep 14, 2005
...the Food and Drug Administration, voted 10 to 5 that Revlimid should be approved to treat anemia in patients with a particular form of myelodysplastic syndromes ...
- New York Times
FDA Panel to Mull Revlimid Safety Sep 13, 2005
Celgene hopes to have Revlimid approved as a treatment for patients with transfusion-dependent anemia as a result of myelodysplastic syndromes. ...
- TheStreet.com
UPDATE 2-FDA asks for more info on MGI Pharma cancer drug Sep 1, 2005
...lower. The drug, called Dacogen, aims to treat myelodysplastic syndromes, a group of blood disorders that can lead to leukemia. ...
- Reuters
Approvable Letter Received from the FDA for Dacogen(TM) ... Sep 1, 2005
...an approvable letter from the US Food and Drug Administration (FDA) for Dacogen(TM) (decitabine) injection for the treatment of myelodysplastic syndromes (MDS ...
- Genetic Engineering News
MGI, SuperGen Get Dacogen Approvable Letter, Have Hope Sep 2, 2005
The FDA issued an approvable letter for Dacogen (decitabine) injection, a treatment for myelodysplastic syndromes (MDS) that is partnered between MGI Pharma Inc ...
- BioWorld Online (subscription)
Bone marrow donors of local man's descent difficult to find Sep 24, 2005
The problem is that Steinberg -- who was diagnosed with myelodysplastic syndromes, which can lead to leukemia -- likely needs a donor of Eastern European ...
- Contra Costa Times
Revlimid®/Dexamethasone Effective Initial Therapy for Multiple ... Sep 21, 2005
...for this disease. Revlimid is currently under FDA review for approval in the treatment of myelodysplastic syndromes. Patients with ...
- Cancer Consultants (press release)
Revlimid® and Dexamethasone Highly Active in Newly Diagnosed ... Sep 23, 2005
...antimyeloma effects. Revlimid has recently been submitted to the FDA for review of treatment of myelodysplastic syndromes (MDS). Revlimid ...
- Cancer Consultants (press release)
GOOD NEIGHBOR: JACQUIE OLIVERIUS Sep 21, 2005
Foundation is hosting a donor recruitment drive for Elliot Steinberg of Martinez, a husband and father of two children, who has Myelodysplastic Syndromes (MDS ...
- Walnut Creek Journal
Consumer News Sep 14, 2005
US Food and Drug Administration advisers voted 10-5 Wednesday to recommend the agency clear Revlimid to treat myelodysplastic syndromes. ...
- Salt Lake Tribune
Business briefs, September 15 Sep 14, 2005
A panel of Food and Drug Administration advisers voted 10-5 to recommend that the agency clear Revlimid to treat myelodysplastic syndromes. ...
- Rocky Mountain News
Zacks.com announces that Nadine Wong Highlights: Celgene and ... Sep 22, 2005
7. Nadine Wong and her team are excited for Celgene and the prospects for Revlimid to be prescribed as a treatment for myelodysplastic syndromes (MDS-q). Based ...
- Business Wire (press release)
US FDA staff raise issues with Celgene drug Sep 12, 2005
Celgene is seeking FDA clearance to sell Revlimid to treat anemia in patients with potentially fatal blood disorders known as myelodysplastic syndromes (MDS). ...
- Reuters
Celgene halted for FDA vote Sep 14, 2005
Celgene is seeking to have Revlimid approved for the treatment of transfusion-dependant anemia due to certain myelodysplastic syndromes, a group of blood cell ...
- MarketWatch
Celgene stock dips ahead of Revlimid panel Sep 13, 2005
The company hopes to get the drug approved to treat transfusion-dependent patients with low- and intermediate-risk of myelodysplastic syndromes, or MDS, who ...
- BusinessWeek
Cramer's 'Mad Money' Recap: 'Timber!' Sep 13, 2005
Celgene rose 10% Monday when word leaked that its Revlimid drug for myelodysplastic syndromes (MDS) does not have the safety concerns people feared. ...
- TheStreet.com
US FDA staff raise issues with Celgene anemia drug Sep 12, 2005
Celgene is seeking FDA clearance to sell Revlimid to treat anemia in patients with blood disorders known as myelodysplastic syndromes. ...
- Reuters
US panel supports Celgene anemia drug Revlimid Sep 14, 2005
10-5 to recommend approval of Celgene Corp.'s Revlimid to treat anemia in patients with potentially fatal blood disorders known as myelodysplastic syndromes. ...
- Reuters AlertNet
US panel supports Celgene anemia drug Revlimid Sep 14, 2005
Corp.'s (CELG.O: Quote, Profile, Research) Revlimid to treat anemia in patients with potentially fatal blood disorders known as myelodysplastic syndromes. ...
- Reuters
Celgene Gets FDA Panel Support Sep 14, 2005
The anemia Celgene is targeting with the drug is associated with myelodysplastic syndromes, a group of blood and bone marrow sicknesses in which unhealthy ...
- TheStreet.com
Celgene drug gets surprise nod from FDA Sep 14, 2005
...support of Revlimid, also known as lenalidomide, a treatment for patients with transfusion-dependent anemia stemming from myelodysplastic syndromes, which is a ...
- CNN
MGI, SuperGen Hit After Hours Sep 1, 2005
...approval from the Food and Drug Administration for the Dacogen injection, a treatment for a group of bone marrow diseases called myelodysplastic syndromes. ...
- TheStreet.com
Celgene May Outgrow Peers Sep 14, 2005
Drug Administration has recommended approval of Celgene's Revlimid, a treatment for transfusion-dependent anemia due to myelodysplastic syndromes with deletion ...
- Forbes
New warning issued for colorectal drug Sep 14, 2005
...panel for cancer drugs recommended approval for a drug to treat anemia in people with certain kinds of blood disorders called myelodysplastic syndromes, or MDS ...
- USA Today
FDA needs more data to approve company's new drug Sep 1, 2005
...profile) received an approvable letter from the US Food and Drug Administration for Dacogen injection for the treatment of myelodysplastic syndromes (MDS), a ...
- MarketWatch
Biotech Stocks Biopharma indexes inch up, Celgene halted Sep 14, 2005
...scheduled to hold a vote later today on whether to recommend Revlimid be approved to treat a type of anemia associated with myelodysplastic syndromes, a group ...
- MarketWatch
Vical, Celgene help pace biotech gains Sep 15, 2005
...the agency approve its drug Revlimid for the treatment of transfusion-dependant anemia caused by blood cancers known at myelodysplastic syndromes, or MDS. ...
- MarketWatch
Will Albertson's Go On Sale? Sep 2, 2005
...that they received an approvable letter from the Food and Drug Administration (FDA) for Dacogen injection, which is a treatment of myelodysplastic syndromes. ...
- BusinessWeek
Stocks to Watch Sep 1, 2005
...profile) said they have received an approvable letter from the Food and Drug Administration for Dacogen injection, used to treat myelodysplastic syndromes. ...
- MarketWatch
The Week Ahead: Sept. 12-16 Sep 9, 2005
Administration will meet to discuss Revlimid, a new drug being developed by Celgene (nasdaq: CELG - news - people ) to treat myelodysplastic syndromes, a type ...
- Forbes
Health Stocks in Motion Sep 2, 2005
...received an approvable letter from the Food and Drug Administration for Dacogen injection, which is used for the treatment of myelodysplastic syndromes. ...
- TheStreet.com
Celgene Revlimid Dose, Toxicity And Single-Arm Study Questions ... Sep 13, 2005
FDA’s “key issues� with Celgene’s myelodysplastic syndromes therapy Revlimid include whether the single-arm pivotal trial can be used to show clinical ...
- FDA Advisory Committee
FDA panel reportedly backs Celgene's cancer drug Sep 14, 2005
...is seeking to have the drug Revlimid approved for the treatment of transfusion-dependent anemia due to certain blood cancers known as myelodysplastic syndromes ...
- Investor's Business Daily (subscription)
FDA panel backs Celgene's cancer drug Sep 14, 2005
NJ-based Celgene wants Revlimid approved for the treatment of transfusion-dependent anemia linked to certain blood cancers known as myelodysplastic syndromes. ...
- Investor's Business Daily (subscription)
ODAC Votes In Favor Of Expanded Tarceva Label Sep 13, 2005
Today, the same panel will vote on Revlimid (lenalidomide, from Celgene Corp.), a product for myelodysplastic syndromes, and Arranon (nelarabine, from ...
- BioWorld Online (subscription)
FDA panel backs Celgene's cancer drug; shares gain Sep 14, 2005
Celgene wants Revlimid approved for the treatment of transfusion-dependent anemia caused by certain blood cancers known as myelodysplastic syndromes, or MDS. ...
- Investor's Business Daily (subscription)
FDA panel backs Celgene cancer drug Sep 14, 2005
The current application before the FDA is for the treatment of myelodysplastic syndromes, the creation of abnormal, immature blood cells in bone marrow. ...
- Newark Star Ledger
Celgene gets good news on blood disorder drug Sep 15, 2005
...the drug. In recent trials, Revlimid was found to be much more powerful than expected in treating myelodysplastic syndromes. With ...
- NorthJersey.com
SGX Latest To File For IPO Sep 2, 2005
...for use in combination with other leukemia medications, as a treatment for various solid tumors and as a treatment for myelodysplastic syndromes, better known ...
- SanDiego.com
MGI Pharma "market outperform" Sep 2, 2005
...morning, the analysts mention that the company and SuperGen have received an approvable letter for Dacogen in the treatment of myelodysplastic syndromes (MDS). ...
- New Ratings
Arch Coal, Watson Pharma, and more Sep 2, 2005
...(SUPG) said they have received an approvable letter from the Food and Drug Administration for Dacogen injection, used to treat myelodysplastic syndromes. ...
- Investor's Business Daily (subscription)
FDA to Expedite Review of Bayer, Onyx Kidney Cancer Drug and ... Sep 15, 2005
The anemia Revlimid targets is associated with myelodysplastic syndromes, a group of blood and bone marrow sicknesses in which unhealthy cells develop and ...
- Financial News USA (press release)
Street Chatter: Celgene, Northwest Airlines, and Newmont Mining Sep 14, 2005
The medication treats a type of anemia that is associated with myelodysplastic syndromes, a group of diseases where the bone marrow doesn't produce enough ...
- Schaeffers Research
Structural GenomiX Changes Corporate Name to SGX Pharmaceuticals Aug 31, 2005
In addition, SGX is developing Troxatyl for the treatment of Myelodysplastic Syndromes, or MDS, as well as for various solid tumors. ...
- PR Newswire (press release)
Confessions of a golfaholicJul 30, 2005
MDS, or myelodysplastic syndromes is a group of diseases in which the bone marrow fails to produce blood cells in the normal manner and often progresses to ...
- The Trentonian
Celgene Corporation Reports Record Operating Performance and Key ...Jul 28, 2005
...regulatory filings, Celgene increased R&D expenditures in REVLIMID® Phase II and Phase III regulatory programs in myelodysplastic syndromes, and pivotal Phase ...
- Yahoo News
Celgene 2Q profit increases fourfoldJul 28, 2005
...for the quarter to $49 million to finance clinical trials for its drug Revlimid for the treatment of bone marrow cancer and myelodysplastic syndromes, or the ...
- BusinessWeek
The Ratings GameJul 28, 2005
Dacogen is an investigational anti-cancer drug designed to treat patients with myelodysplastic syndromes or MDS, a cancer of the bone marrow that is often ...
- MarketWatch
Cytokinetics, Incorporated Reports Second Quarter 2005 Financial ...Jul 27, 2005
...standard therapies and the other clinical trial is enrolling patients with acute leukemia, chronic myelogenous leukemia or advanced myelodysplastic syndromes. ...
- Business Wire
Log in Register NowJul 26, 2005
Myelodysplastic Syndromes (MDS) is a group of diseases in which the bone marrow fails to produce blood cells in the normal manner and often progresses to acute ...
- Genetic Engineering News
Major Response with Aranesp(R) in Anemic Patients with ...Jul 10, 2005
...of 500 mcg of Aranesp(R) (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS). ...
- Medical News Today
Highlights of rising and falling US stocksJul 26, 2005
...overhangs continue for the company with investors concerned about the longer-term outlook for Vidaza, Pharmion's treatment for myelodysplastic syndromes. ...
- Investor's Business Daily (subscription)
Pharmion Announces Second Quarter 2005 Sales of $56.3 MillionJul 25, 2005
...includes over 30 Company- and investigator- sponsored clinical studies examining the use of Vidaza in the treatment of Myelodysplastic Syndromes (MDS), other ...
- Yahoo News
MGI PHARMA to Acquire Guilford PharmaceuticalsJul 21, 2005
...hospitals for Aloxi injection in chemotherapy-induced nausea and vomiting (CINV) and, upon approval, for Dacogen injection in myelodysplastic syndromes (MDS). ...
- Business Wire
Amgen's Stock Surges On Second-Quarter SurpriseJul 20, 2005
Other data from a Phase II study indicated Aranesp might cause a major response in anemic patients with myelodysplastic syndromes. ...
- BioWorld Online (subscription)
MGI Pharma Buys Out Guilford For $177.5M In Cash, StockJul 21, 2005
MGI, for its part, is awaiting word from the FDA on Dacogen (decitabine) for myelodysplastic syndromes, a cancer of the bone marrow, with a PDUFA date of Sept. ...
- BioWorld Online (subscription)
Amgen's Second Quarter 2005 Adjusted Earnings Per Share Increased ...Jul 19, 2005
New interim data for Aranesp suggesting a major response in anemic patients with myelodysplastic syndromes (MDS) was recently presented at the 17th ...
- Genetic Engineering News
Millennium's New CEO Targets Profit Next YearJul 1, 2005
...company wants approval to market the compound for transfusion-dependent patients suffering low- and intermediate-risk myelodysplastic syndromes with deletion ...
- BioWorld Online (subscription)
MGI PHARMA Reports Second Quarter ResultsJul 13, 2005
...activities, including the September 1 Prescription Drug User Fee Act (PDUFA) goal date for Dacogen(TM) injection in myelodysplastic syndromes (MDS), submission ...
- Business Wire
Amgen drug promising for bone marrow disorderJul 7, 2005
...in Geneva on Wednesday, the Thousand Oaks company announced positive interim results for patients with anemia who have myelodysplastic syndromes (MDS) treated ...
- Ventura County Star (subscription)
Amgen Offer Update on Aranesp for Anemic Patients and Nanogen ...Jul 7, 2005
...use of 500 mcg of Aranesp® (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS ...
- Financial News USA
Health Canada grants Priority Review for (PR)Exjade(TM) for ...Jul 14, 2005
...required to treat certain types of anemias and other disorders, including thalassemia, sickle cell disease, other rare anemias, and myelodysplastic syndromes. ...
- Canada NewsWire
Celgene: A Biotech With Profits And A PipelineJul 6, 2005
...and Pile is encouraged by positive clinical trial data for the drug to treat a subset of transfusion-dependent patients suffering from myelodysplastic syndromes ...
- Forbes
This page is updated on a monthly basis if relevant articles are available. If you are looking for further information on
Myelodysplastic Syndromes
you may want to try searching the Internet using the Google search box below.
|
|
|
